The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has ...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lxWyAk
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
-
by Alison M. Hixon, Guixia Yu, J. Smith Leser, Shigeo Yagi, Penny Clarke, Charles Y. Chiu, Kenneth L. Tyler In 2014, the United States exp...
-
Viruses, Vol. 10, Pages 61: Virus–Bacteria Interactions: Implications and Potential for the Applied and Agricultural Sciences Viruses doi: ...
-
This paper proposes an enhanced ant colony optimization with dynamic mutation and ad hoc initialization, ACODM-I, for improving the accuracy...
-
Hypopharyngeal Cancer Pharmaceutical and Healthcare Pipeline Review, H1 2017 Medgadget (blog) Latest Pharmaceutical and Healthcare di...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου